Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
BFRI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.42
Previous CloseN/A
Volume12.39M
Average Volume (3M)91.16K
Market Cap
$6.61M
Enterprise Value$8.68M
Total Cash (Recent Filing)$5.91M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 31, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding8,873,932
10 Day Avg. Volume69,805
30 Day Avg. Volume91,161
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.19
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.45
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$7.00Price Target Upside845.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Biofrontera News
PremiumCompany Announcements
Biofrontera Inc. Reports Record Sales and Strategic Advances
PremiumCompany Announcements
Biofrontera Inc. Reports Record Revenue Growth in 2024
---
BFRI FAQ
What was Biofrontera’s price range in the past 12 months?
Biofrontera lowest stock price was $0.65 and its highest was $2.42 in the past 12 months.
What is Biofrontera’s market cap?
Biofrontera’s market cap is $6.61M.
When is Biofrontera’s upcoming earnings report date?
Biofrontera’s upcoming earnings report date is May 31, 2025 which is in 49 days.
How were Biofrontera’s earnings last quarter?
Biofrontera released its earnings results on Mar 21, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.165.
Is Biofrontera overvalued?
According to Wall Street analysts Biofrontera’s price is currently Undervalued.
Does Biofrontera pay dividends?
Biofrontera does not currently pay dividends.
What is Biofrontera’s EPS estimate?
Biofrontera’s EPS estimate is -0.22.
How many shares outstanding does Biofrontera have?
Biofrontera has 8,873,932 shares outstanding.
What happened to Biofrontera’s price movement after its last earnings report?
Biofrontera reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -16.505%.
Which hedge fund is a major shareholder of Biofrontera?
Currently, no hedge funds are holding shares in BFRI
---
Company Description
Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
---
BFRI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with record sales, FDA approval for extended treatment options, successful restructuring of agreements, and improved financial metrics. However, the net loss in Q4 and minimal unit growth for Ameluz are notable concerns.Read More>---
BFRI Stock 12 Month Forecast
Average Price Target
$7.00
▲(845.95% Upside)
Technical Analysis
Aclaris Therapeutics
―
Verona Pharma
―
Evolus
―
Arcutis Biotherapeutics
―
Journey Medical Corp
―
Best Analysts Covering BFRI
1 Year
1 Year Success Rate
0/13 ratings generated profit
1 Year Average Return
-63.55%
reiterated a buy rating 20 days ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -63.55% per trade.
---